Post Thumb

Team at Christiana Care develops new gene editing system that could help fight cancer

Dr. Eric Kmiec, Ph.D., is the director of the Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System. He and his

Post Thumb

Chicago Teen Leads Way To Colon Cancer Cure

#tbt #bhm #allstate #ad pic.twitter.com/Xzh5lD2x0F – Keven Stonewall (@thatkevenguy) February 9, 2017 While most of his peers were focused on graduating and figuring out “what’s next?”, Keven Stonewall was discovering colon cancer breakthroughs during his last year of the high school. As a student working at a Rush University lab during his senior year, the…

Post Thumb

Insilico Medicine launches Aging.AI — deep-learned predictor of age trained on blood tests

Insilico Medicine launched aging.AI, a system allowing users to guess their age and gender by entering the results of their blood test.

Inflammation and Anti-Inflammatories

Author: Rima Martin and Adam Alonzi     We usually consume what our hearts and stomachs desire, but everyday foods can damage our health if taken in excess. Our body’s inflammatory process a wonderful part of the immune system. If your immune system and its ability to intelligently manage inflammation became impaired you would have […]

Post Thumb

Cancer-associated mutations are common in patients with unexplained low blood counts

Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood. The researchers found the condition surprisingly common in older patients with low blood counts.

Post Thumb

New Appoach targets Cancer Stem Cells and uses tens of thousands of animal models | NextBigFuture.com

Stemcentrx, has raised $500 million and is valued at $3 billion, people familiar with its finances say, a nearly unprecedented value for a company with no revenue, facing the usual R and D obstacles, and that almost no one has heard of. Silicon Valley is used to “unicorns,” those private, usually profitless, and fast-growing tech companies worth a billion dollars or more, like Snapchat, Square, and Uber. Now the same phenomenon is spreading to biotech, where investors are throwing money at companies that promise to beat the historically low odds of drug success. The company is unusual because it’s betting on a scientific idea that’s not universally accepted-that cancer is caused not by any cell that goes rogue, but by rare and powerful cancer stem cells. Stemcentrx’s contrarian premise-that stem cells can be bad, not good-has drawn some impressive backers, including Sequoia Capital, Elon Musk, and most notably Founders Fund, the investment firm led by Peter Thiel, the Midas-touch

Post Thumb

Researchers thwart cancer cells by triggering ‘virus alert’

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system “virus alert” that may one day boost cancer patients’ response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells’ ability to avoid detection and destruction by the immune system.

Post Thumb

Researchers thwart cancer cells by triggering 'virus alert'

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system “virus alert” that may one day boost cancer patients’ response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells’ ability to avoid detection and destruction by the immune system.

Post Thumb

Jimmy Carter and His ‘Breakthrough' Cancer Drug

Former president Jimmy Carter, who announced Thursday he has melanoma that had spread to his liver and brain, is being treated with two cutting-edge therapies that offer new hope to the 76,000 Americans diagnosed annually with this type of cancer. Carter, 90, explained in a news conference at the Carter Center in Atlanta that melanoma – most commonly occurring as skin cancer, but which can also cause internal tumors – had formed a mass in his liver, as well as …

Post Thumb

Jimmy Carter and His ‘Breakthrough’ Cancer Drug

Former president Jimmy Carter, who announced Thursday he has melanoma that had spread to his liver and brain, is being treated with two cutting-edge therapies that offer new hope to the 76,000 Americans diagnosed annually with this type of cancer. Carter, 90, explained in a news conference at the Carter Center in Atlanta that melanoma – most commonly occurring as skin cancer, but which can also cause internal tumors – had formed a mass in his liver, as well as …